What is it about?
Some types of human papillomavirus (HPV) can cause cancer if they persist in the body. To survive and spread, HPV carefully controls when it copies its DNA and produces new virus particles. Normally, these steps only happen after infected skin cells have matured. How the virus prevents these processes from starting too early has not been fully understood. In this study, we show that a viral protein called E8^E2 acts as a gatekeeper, stopping HPV from switching into its productive replication phase in immature skin cells. When E8^E2 is disabled, HPV begins copying its DNA too early, produces a late viral protein called E4, and disrupts the normal cell cycle. As a result, infected cells stop dividing, making it difficult for the virus to maintain its DNA in the form needed for long-term infection. We also found that disrupting the cellular protein complexes that work with E8^E2 produces the same effects, highlighting their importance in controlling the viral life cycle.
Featured Image
Why is it important?
These findings improve our understanding of how HPV balances long-term persistence with virus production. They also identify the interaction between E8^E2 and its cellular partners as a promising target for new antiviral treatments that could interfere with HPV infection before it leads to disease.
Perspectives
High-risk HPV infections are responsible for hundreds of thousands of cancer cases worldwide each year, yet there are no antiviral drugs that specifically eliminate HPV infections. Understanding how the virus controls its life cycle is therefore essential for identifying new therapeutic opportunities. Our study reveals that the viral protein E8^E2 plays a central role in preventing HPV from entering its productive replication phase too early, allowing the virus to establish and maintain long-term infections. By identifying the interaction between E8^E2 and the cellular NCoR/SMRT co-repressor complexes as a key regulatory mechanism, our findings point to a potential new antiviral target. Future studies will be needed to determine whether disrupting this interaction can be developed into a safe and effective treatment for persistent HPV infections.
Frank Stubenrauch
Eberhard Karls Universitat Tubingen
Read the Original
This page is a summary of: Inhibition of high risk HPV31 E8^E2 repressor activity enables differentiation-independent genome amplification and E4 expression, PLoS Pathogens, June 2026, PLOS,
DOI: 10.1371/journal.ppat.1014330.
You can read the full text:
Contributors
The following have contributed to this page
